{"entity":{"id":"paper-brandl-hepatitis-liver-cancer-kyrgyzstan-lanepe-2026","kind":"paper","name":"Liver cirrhosis and liver cancer attributable to hepatitis B and C in Kyrgyzstan, 2019 to 2024","aka":[],"tldr":"Among 572 people with liver cancer in hospitals and oncology centres in Bishkek, Osh and Jalal-Abad, hepatitis B accounted for 32% and hepatitis C for 32%. Half of the liver cancer patients tested for hepatitis D antibodies were positive.","summary":"Published as \"Liver cirrhosis and hepatocellular carcinoma attributable to hepatitis B and C in Kyrgyzstan, 2019-2024: a prospective and retrospective study\", led by the Robert Koch Institute in Berlin with Kyrgyz co-authors and funded by Germany's Global Health Protection Programme. The authors collected information on patients with cirrhosis or hepatocellular carcinoma from medical records in clinical hospitals and oncology centres in Bishkek, Osh and Jalal-Abad, prospectively from August 2023 to April 2024 and retrospectively from January 2019 to July 2023.","asOf":"2026-11-16","links":[{"label":"Lancet Reg Health Eur 2026","url":"https://doi.org/10.1016/j.lanepe.2026.101665"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/41971035/"}],"tags":[],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kg-ministry-of-health","kg-national-center-of-oncology-and-hematology","kg-osh-interregional-oncology-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"The Lancet Regional Health - Europe","year":2026,"doi":"10.1016/j.lanepe.2026.101665","pmid":"41971035","authors":"Brandl M, Nurmatov Z, Sattarova G, et al.","paperType":"observational","findings":["Among 914 participants with cirrhosis, 46% of cases were attributable to hepatitis B (95% CI 42 to 49%) and 25% to hepatitis C (95% CI 22 to 28%).","Among 572 participants with hepatocellular carcinoma, the fractions attributable to hepatitis B (182) and hepatitis C (183) were both 32% (95% CI 28 to 36%).","Of those tested for hepatitis D antibodies, 78% of cirrhosis patients (306 of 390) and 50% of liver cancer patients (44 of 88) were positive."],"whatItMeans":"About six in ten of the liver cancers studied (348 of 572, counting the 17 people with both infections once) were attributed to hepatitis B or C, infections that can be prevented by vaccination or treated. The authors call for earlier testing and treatment. Liver cancer is the third commonest cause of cancer death in IARC's 2024 estimate for Kyrgyzstan.","caveats":["Hospital and oncology centre records in three cities, not a population sample.","Not every patient was tested for every virus; the hepatitis D figures cover a subset."]},"route":"/key-papers/paper-brandl-hepatitis-liver-cancer-kyrgyzstan-lanepe-2026/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"institution":[{"id":"kg-ministry-of-health","kind":"institution","name":"Ministry of Health of the Kyrgyz Republic","route":"/institutions/kg-ministry-of-health/"},{"id":"kg-national-center-of-oncology-and-hematology","kind":"institution","name":"National Center of Oncology and Hematology of the Kyrgyz Republic","route":"/institutions/kg-national-center-of-oncology-and-hematology/"},{"id":"kg-osh-interregional-oncology-centre","kind":"institution","name":"Osh Interregional Oncology Centre","route":"/institutions/kg-osh-interregional-oncology-centre/"}]}}